Molecular Skin Therapeutics

Business Data, Corporate Office and Headquarter Address

About

Molecular Skin Therapeutics is Biotechnology in United States that focus on Provider business. They cover business area such as Provider, skin therapeutic service, Palo Alto, California, skin therapy, a series, Netherton Syndrome.

Business Type

Biotechnology

Country

United States

Founded

-

Company Focus

Provider

Website

-

Corporate Office and Headquarter Office address:

165 University Avenue
Suite 5
Palo Alto, CA 94301
United States

Phone number:

Private

Office Opening Hours*:

Monday 9.30 - 17.00
Tuesday 9.30 - 17.00
Wednesday 9.30 - 17.00
Thursday 9.30 - 17.00
Friday 9.30 - 17.00
Saturday Closed
Sunday Closed

Business Coverage

Providerskin therapeutic servicePalo AltoCaliforniaskin therapya seriesNetherton Syndrome

* We use standard office opening hours in near Molecular Skin Therapeutics's location as default value for unknown and outdated data. For more valid info, please verify the info from more trusted sources like GoogleMyBusiness, Yelp, FourSquare or similar services.

Molecular Skin Therapeutics Frequently Asked Questions

What or who is Molecular Skin Therapeutics?

Molecular Skin Therapeutics is Biotechnology business from United States that founded in - ( years old in ), Molecular Skin Therapeutics business is focusing on Provider.

Where is Molecular Skin Therapeutics headquarter and corporate office address?

Molecular Skin Therapeutics headquarter office and corporate office address is located in 165 University Avenue Suite 5 Palo Alto, CA 94301 United States.

Where is Molecular Skin Therapeutics country origins?

Molecular Skin Therapeutics was founded in United States.

What is Provider business focus on?

In , Molecular Skin Therapeutics is currently focus on Provider sector.

Provider Business Interest from Google Trend

Above is snippet of Google Trends for "Provider" term, if you have problem loading the snippet, please visit here: Google Trend.

Disclaimer: This website is not affiliated with Molecular Skin Therapeutics, any government agency, does not create this data, vouch for its accuracy, or guarantee that it is the most recent data available. The data displayed is available through open government websites and public online directory. This website expressly disclaims the accuracy, adequacy, or completeness of any data and shall not be liable for any errors, omissions or other defects in, delays or interruptions in such data, or for any actions taken in reliance thereon.